...of stem cell therapies in children with relapsed neuroblastoma and sarcoma. Over the next year, Serametrix...
...company's panel of cancer antigens from patients enrolled in the trials. Details were not disclosed. Serametrix Corp....

...MCC) and malignant melanoma. Terms were not disclosed. OncoSec Medical Inc. (OTCBB:ONCS), San Diego, Calif. Serametrix Corp....

...Research (New York, N.Y.) to patents covering NY-ESO-1 last year (see BioCentury, Oct. 19, 2009). Serametrix Corp....

...to the institute's patents covering tumor antigen NY-ESO-1. The partners will use the IP and Serametrix's...
...patients. The Institute will receive an equity stake in Serametrix. Financial terms were not disclosed. Serametrix Corp....